Page 343 - Binder2

flip that logic: they survive because they’re easy to
replicate—with the right tools, data, and oversight.

And once that power shifts—from factories to farms, from
franchises to frameworks—the future no longer belongs to
those who guard the gates.

It belongs to those who share the seeds.

That’s not just uncomfortable for the pharmaceutical
establishment.
It’s terrifying.

6.5 – Why They Haven’t Adopted It

If edible biologics are cheaper, more scalable, potentially
more durable, and safer to produce—why hasn’t Big
Pharma embraced them?

It’s not a scientific issue.

It’s a structural one.

The pharmaceutical industry isn’t optimized for disruptive
innovation. It’s optimized for risk management, revenue
protection, and regulatory alignment. The business model
doesn’t reward the best ideas—it rewards the safest path to
the next quarterly report.

And edible biologics?
They break that model.

341